Abstract: The present invention relates to novel compounds of formula (1), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory disease.

Abstract: The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

Abstract: The present invention relates to novel compounds of Formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

Abstract: The present invention relates to novel compounds of Formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

Abstract: The present invention relates to novel compounds of Formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

Abstract: The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

Abstract: A compound of formula (I) or a salt, solvate, or physiologically functional derivative thereof, wherein: m is an integer of from 2 to 8; n is an integer of from 2 to 5; with the proviso that m+n is 4 to 10; R4 and R5 are independently selected from hydrogen and C1-4alkyl with the proviso that the total number of carbon atoms in R4 and R5 is not more than 4; R6 and R7 are independently selected from hydrogen and C1-4alkyl with the proviso that the total number of carbon atoms in R6 and R7 is not more than 4, and Ar1 is a group selected from (a), (b), (c) and (d).

Abstract: The present invention relates to novel compounds of formula (I), or a salt, solvate, or physiologically functional derivative thereof, to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

Abstract: The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

Abstract: The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases.

Abstract: Compounds capable of providing a therapeutic effect at a target site within a human or animal body with reduced systemic potency to said body are identified by comparing the susceptibility to hydrolysis of the compound in the presence of a purified lactonase enzyme or a recombinant form of it to the corresponding susceptibility in the absence of said lactonase enzyme, and then selecting a compound on the basis of enhanced susceptibility to hydrolysis in the presence of said lactonase enzyme

Abstract: Certain novel imidazole derivatives N-substituted by a vinyl group itself carrying a mevalonic acid derivative or corresponding lactone are inhibitors of HMG-CoA reductase and are useful for lowering blood plasma cholesterol levels.The compounds are of general formula (I): ##STR1## in which one of the groups R.sup.1 and R.sup.2 represents a C.sub.1-6 alkyl group optionally substituted by one to three halogen atoms and the other represents a phenyl ring optionally substituted by one to five substituents selected from halogen atoms and hydroxyl, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, S(O).sub.n C.sub.1-3 alkyl, (CH.sub.2).sub.m NR.sup.a R.sup.b, (CH.sub.2).sub.m NR.sup.c COR.sup.d and trifluoromethyl groups;R.sup.3 represents a phenyl ring optionally substituted by one to five substituents selected from halogen atoms and hydroxyl, C.sub.1-3 alkyl, C.sub.1-3 alkoxy, S(O).sub.n C.sub.1-3 alkyl, (CH.sub.2).sub.m NR.sup.a R.sup.b, (CH.sub.2).sub.m NR.sup.c COR.sup.

Abstract: A compound of formula (I) ##STR1## is prepared by cyclizing a compound of formula (IIa) or (IIb) or a mixture thereof ##STR2## wherein X is hydroxyl or halogen and R.sup.1 and R.sup.2 independently, represent hydroxy protecting groups) followed by removal of the protecting groups R.sup.1 and R.sup.2.The compound (I) is of use as an intermediate in the stereoselective preparation of (.+-.) trans-5-fluoro-2,3,3a,9a-tetrahydro-1H-[1,4]benzodioxino[2,3-c] pyrrole, which is a selective .beta..sub.2 -adrenoreceptor antagonist and is thus of potential value, in particular, for the treatment or prevention of depression.